Rejected from Lancet Infectious Diseases? Where to Submit Next

The useful question is not "what journal is slightly easier?" It is "what did Lancet Infectious Diseases not believe about this manuscript?"

If the editor did not believe the work had international clinical or public-health consequence, then the next journal should have a more focused clinical, national, implementation, microbiology, or pathogen-specific audience. If the editor believed the question mattered but the manuscript package was thin, then moving journals without repair is wasteful. If reviewers raised reporting or analysis concerns, a lower-impact journal will usually raise the same concern because the weakness is visible in the paper, not in the venue.

Use the rejection letter to classify the failure:

Lancet Infectious Diseases is not just another infectious-disease journal with a higher impact factor. The source-backed fit screen is different. The journal's public positioning points toward infectious-disease work that affects clinical practice, public health, policy, and international readers. Its article limits force authors to make the clinical or policy argument quickly. ScienceDirect also reports very fast median first-decision timing for the journal page, which means many manuscripts are filtered before a long external-review process can begin.

That creates a harsh but useful signal. A rejection often means one of three things:

• The paper is good but too local for the journal. A single-country surveillance study, hospital cohort, or regional outbreak analysis can be useful, but Lancet ID needs the reason international readers should act on it.
• The paper is important but under-packaged. The methods, reporting checklist, ethics, registration, figure logic, or limitations may not let editors verify the claim fast enough.
• The paper belongs in a different infectious-disease lane. Clinical management, microbiology mechanism, diagnostic evaluation, antimicrobial resistance, outbreak surveillance, vaccine policy, and public-health implementation do not all belong at the same next journal.

This is why the next submission should be routed by manuscript phenotype, not by prestige ladder.

This page was researched from official Lancet author material, the journal's public scope language, the Lancet submission pages, ScienceDirect's journal page, and Manusights' existing Lancet Infectious Diseases content cluster. In our analysis of the post-rejection routing job, the non-obvious question is not which journal has the next lower selectivity. It is which manuscript component caused the rejection signal: abstract claim, study design, comparator, reporting package, figure logic, cover letter, or limitations.

The specific rejection patterns below are therefore written as a manuscript diagnostic rather than a generic journal list. We see authors waste the next cycle when they treat a Lancet ID rejection as a prestige-ladder problem, but the paper actually has an audience, methods, or evidence-chain problem. In practice, the strongest next journal is the one where the paper's true reader can use the result without the authors exaggerating the claim.

Rebuild for Lancet Infectious Diseases only when the manuscript still has a Lancet-level claim and the rejection exposed a repairable weakness. This is most plausible after an invited revision, a detailed review, or an editorial note that points to specific evidence gaps.

Good reasons to rebuild:

• The primary finding changes treatment, prevention, diagnostic strategy, stewardship, surveillance, vaccine policy, or outbreak response across settings.
• The rejection letter questioned presentation, not the underlying question.
• A missing sensitivity analysis, subgroup analysis, reporting checklist, data availability statement, or limitations paragraph can materially strengthen the claim.
• The manuscript's strongest figure or table was not visible early enough in the abstract, Research in Context section, or cover letter.

Bad reasons to rebuild:

• You only want to keep chasing the brand.
• The study is a single-center cohort whose conclusion depends on local practice.
• The novelty rests on a pathogen, population, or intervention that is already well covered.
• Reviewers identified a design limitation that cannot be fixed without new data.

If you do rebuild, make the repair visible in the first page. Editors should not need to search the supplement to discover why the paper is now stronger.

Clinical Infectious Diseases is often the best next journal when the paper is clinically important but does not need a Lancet specialty platform. The fit is strongest for patient-care decisions, antimicrobial stewardship, diagnostic pathways, clinical epidemiology, guideline-relevant findings, and infectious-disease management work where clinicians are the primary audience.

Choose CID when the manuscript can answer a practical question:

• What should an infectious-disease clinician do differently?
• Which diagnostic, treatment, prevention, or stewardship decision changes?
• Which patient group, comparator, endpoint, and effect size support that decision?
• Can the claim survive beyond the original hospital, country, cohort, or outbreak context?

If your answer is "the finding is biologically interesting" rather than "the finding changes clinical decision-making," CID may not be the right next target. Journal of Infectious Diseases or a microbiology journal may fit better.

A common Lancet ID rejection pattern is a useful outbreak or surveillance manuscript framed too grandly. The work may be valuable, but the global lesson may be narrower than the authors claimed.

Move toward Emerging Infectious Diseases, Eurosurveillance, International Journal of Infectious Diseases, or a regional public-health journal when the manuscript's real value is:

• early detection of an emerging pathogen or variant;
• outbreak investigation with public-health lessons;
• antimicrobial-resistance surveillance;
• vaccine effectiveness or implementation monitoring;
• geographic spread, travel, zoonotic transmission, or health-system preparedness;
• public-health methods that other surveillance teams can reuse.

The rewrite should reduce overclaiming. Do not pretend every outbreak analysis changes global policy. Make the action specific: what a surveillance team, clinician, lab, public-health agency, or policy group can do with the finding.

If the rejected manuscript is mainly about mechanism, pathogen biology, immune response, diagnostic assay performance, laboratory validation, or antimicrobial susceptibility, the next target should follow the scientific center of gravity.

The clearest warning sign is a clinical abstract wrapped around laboratory evidence. Lancet Infectious Diseases may reject because the manuscript cannot prove a direct clinical or policy consequence. A microbiology or translational infectious-disease journal can be stronger if the paper's real contribution is mechanistic.

Before you submit again, rewrite the title, abstract, and final paragraph so they match the actual evidence. A mechanism paper should not promise a clinical change it cannot test. A diagnostic-performance paper should show population, comparator, reference standard, reproducibility, and use case. An antimicrobial-resistance paper should separate surveillance value from treatment recommendation.

In our pre-submission and post-decision review work with manuscripts aimed at Lancet Infectious Diseases, the productive repairs are usually not generic language edits. They are manuscript-routing decisions tied to specific components: the abstract claim, the first figure, the comparator, the methods section, the reporting checklist, the cover letter, the Research in Context framing, and the limitations paragraph.

Three patterns are especially common.

The global-consequence gap. The manuscript reports a real finding but never proves why readers outside the original setting should care. This often appears in single-country cohorts, hospital-based antimicrobial-resistance studies, regional outbreak reports, and retrospective analyses. The repair is not to add vague global language. The repair is to show the mechanism of relevance: shared pathogen behavior, transferable diagnostic decision, health-system lesson, policy implication, treatment consequence, or surveillance method.

The evidence-chain gap. The paper makes a strong clinical or policy claim, but the chain from question to data to analysis to conclusion is hard to audit. The abstract says too much, the methods are thin, the reporting checklist is incomplete, the figure does not carry the main claim, or the limitations paragraph hides the key constraint. Editors and reviewers notice this quickly because Lancet ID articles have limited space. A compact paper must make the evidence path cleaner, not just shorter.

The wrong-audience gap. The strongest readers for the paper are not the readers implied by the target journal. A pathogen-mechanism paper is sent as clinical practice. A local implementation study is framed as global policy. A surveillance result is presented as treatment guidance. These papers often improve after rejection because the next submission finally names the correct audience and writes for that audience.

The practical lesson is simple: after Lancet ID rejection, the manuscript should either become a stronger Lancet-level paper or a more honest paper for a better-matched journal. The worst option is a cosmetic resubmission that preserves the same unsupported claim.